Q3 2024 Tempus AI Inc Earnings Call Transcript
Key Points
- Tempus AI Inc (TEM) reported a 33% revenue growth, reaching $180.9 million for Q3 2024.
- The company's data and services revenue accelerated to 64.4% year-over-year growth, with the data licensing business growing by 86.6%.
- Tempus AI Inc (TEM) announced the acquisition of Ambry Genetics, which is expected to accelerate their path to cash flow and adjusted EBITDA breakeven.
- The acquisition of Ambry Genetics is expected to be synergistic across Tempus AI Inc (TEM)'s product lines and is anticipated to be EBITDA and cash flow positive.
- The company has secured significant contracts and renewals with major pharmaceutical companies, including Merck and BioNTech, indicating strong demand for their data products.
- Tempus AI Inc (TEM) reported an adjusted EBITDA of negative $21.8 million, despite improvements from the previous year.
- The company is still facing challenges in achieving reimbursement for some of its MRD products, which affects the potential growth of this segment.
- There are concerns about the sustainability of Ambry Genetics' 25% growth rate, given uneven growth trends in the hereditary cancer testing market.
- The integration of Ambry Genetics may pose organizational challenges as Tempus AI Inc (TEM) expands into new verticals.
- The data business, despite strong growth, is not expected to sustain its current high growth rate of 87%, indicating potential volatility in future performance.
Thank you for standing by. My name is Brianna, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Tempus AI Third Quarter 2024 Financial Results Conference Call.
(Operator Instructions) I will now turn the conference over to Liz Krutoholow. Please go ahead.
Thank you, Brianna. Good afternoon, and welcome to Tempus third quarter 2024 conference call. This afternoon, Tempus released results for the quarter ending September 30, 2024. Joining me today from Tempus are Eric Lefkofsky, Founder and CEO of Tempus and Jim Rogers, CFO.
Before we begin, I would like to remind you that during this call, management may make forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please visit our 10-Q for the quarter ended September 30, 2024, filed on November 4, 2024 as well as any future reports that we file with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
